Organon & Co (OGN) concluded trading on Wednesday at a closing price of $15.68, with 4.13 million shares of worth about $64.83 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.76% during that period and on December 11, 2024 the price saw a gain of about 3.70%. Currently the company’s common shares owned by public are about 257.54M shares, out of which, 256.98M shares are available for trading.
Stock saw a price change of 2.08% in past 5 days and over the past one month there was a price change of -2.55%. Year-to-date (YTD), OGN shares are showing a performance of 8.74% which increased to 39.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.97 but also hit the highest price of $23.10 during that period. The average intraday trading volume for Organon & Co shares is 2.50 million. The stock is currently trading 1.99% above its 20-day simple moving average (SMA20), while that difference is down -5.73% for SMA50 and it goes to -18.05% lower than SMA200.
Organon & Co (NYSE: OGN) currently have 257.54M outstanding shares and institutions hold larger chunk of about 81.23% of that.
The stock has a current market capitalization of $4.04B and its 3Y-monthly beta is at 0.71. PE ratio of stock for trailing 12 months is 3.11, while it has posted earnings per share of $5.04 in the same period. Its PEG reads 0.64 and has Quick Ratio of 1.21 while making debt-to-equity ratio of 17.75. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OGN, volatility over the week remained 4.01% while standing at 3.24% over the month.
Stock’s fiscal year EPS is expected to drop by -0.39% while it is estimated to increase by 2.73% in next year. EPS is likely to grow at an annualized rate of 4.83% for next 5-years, compared to annual growth of -14.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on September 06, 2024 offering an Underweight rating for the stock and assigned a target price range of between $18 and $20 to it. Coverage by Goldman stated Organon & Co (OGN) stock as a Neutral in their note to investors on November 03, 2023, suggesting a price target of $16 for the stock. On September 21, 2023, Barclays Initiated their recommendations, while on March 16, 2023, Raymond James Initiated their ratings for the stock with a price target of $33. Stock get an Underperform rating from BofA Securities on October 14, 2022.
